Nobel Biocare at a glance
Our brand
The Nobel Biocare brand builds on a heritage going back to Alfred Nobel’s legacy. It represents a pioneering spirit, and is synonymous with scientific leadership and innovation. More
Our heritage
We draw on the industry’s longest heritage – 40 years – of original scientific research and innovation in restorative dentistry, starting with P.-I. Brånemark‘s discovery of osseointegration. We produced the first dental implant and were the first to industrialize the commercial manufacture of dental implants and CAD/CAM-based prosthetics. Since then, we have introduced numerous advanced solutions to the market, many of which have become industry standards. More
Innovation
As the pioneer in our industry, we have a long tradition of innovation and clinical excellence. We provide a leading portfolio of products and solutions to help our customers treat their patients’ needs in the best possible way. Our wide range of top-quality products can restore missing or damaged teeth from crown to root. More
The dental market
Today, millions of people suffer from missing teeth. The penetration of implant-based tooth restorations is still very low, and such treatments offer sustainable growth potential. Furthermore, global market trends, such as changing demographics and patient demands, present attractive opportunities. More
Our customers
We serve dental healthcare professionals around the world, including oral surgeons, general practitioners, specialists, and laboratories. Our products, solutions and services enable them to treat and educate patients with any type of tooth loss. Our commitment to our customers is underpinned by a unique range of training, education and support programs to help them grow their business. More
Organizational excellence
Nobel Biocare has the widest global spread in the industry. In manufacturing, we maintain two innovation centers, three implant and CAD/CAM prosthetics manufacturing sites, and two logistic distribution centers. We have sales, marketing and customer service centers in 34 markets. We employ more than 2’400 dedicated and skilled people from diverse professional and ethnic backgrounds across the globe. In many markets –established and emerging – we hold leading positions.
Revenue 2011 by region (%)
Key financials
| in EUR mn | 2011 | Change (in %) | 2010 | 2009 | 2008 |
|---|
| Revenue | 569.2 | -0.71 | 576.6 | 581.4 | 619.2 |
| Gross profit | 432.5 | -3.5 | 448.0 | 467.9 | 493.6 |
| Profit from operations (EBIT) | 72.1 | -15.1 | 84.9 | 128.6 | 132.9 |
| Profit before tax | 55.5 | -44.8 | 100.4 | 137.3 | 159.4 |
| Profit attributable to owners of Nobel Biocare | 39.8 | -12.9 | 45.7 | 105.8 | 109.7 |
| Cash and cash equivalents2 | 107.5 | -55.1 | 239.5 | 240.7 | 163.4 |
| Shareholders' equity | 281.5 | -12.0 | 320.0 | 317.7 | 267.6 |
| Basic earnings per share (EUR)3 | 0.32 | -12.4 | 0.37 | 0.86 | 0.90 |
| Dividend per share (CHF)3, 4 | 0.15 | -57.1 | 0.35 | 0.55 | 0.55 |
| Share price at year-end (CHF)3 | 10.92 | -38.1 | 17.63 | 34.78 | 21.42 |
1 In local currencies.
2 Including bank overdraft.
3 Figures for 2007 and 2008 adjusted to reflect the 2008 share split.
4 Proposed dividend for 2011.